Product Description
RTP-026 activates tissue reparative pathways by targeting innate immune cells. Our preclinical data shows that RTP-026 works by: Regulating neutrophil and monocyte recruitment to injured tissue, Promoting neutrophil apoptosis and thereby limiting destruction of, surrounding tissue, Removing apoptotic cells through efferocytosis, Promoting macrophage switch towards a pro-resolving phenotype. Together, these orchestrated cellular events contribute to resolution of inflammation and activation of cellular event that support tissue healing. RTP-026 mimics the action of Annexin A1 and initiates resolution and tissue repair through its action on a G-protein coupled receptor expressed on the surface of leukocytes. (Sourced from: https://resotherpharma.com/research/#:~:text=RTP%2D026%20activates%20tissue%20reparative,limiting%20destruction%20of%20surrounding%20tissue)
Mechanisms of Action: FPR2 Modulator
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ResoTher Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for RTP-026](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic: Denmark
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Myocardial Infarction|ST Elevation Myocardial Infarction
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2023-509182-21-00 | P2 |
Not yet recruiting |
Myocardial Infarction |
2025-12-31 |
|
ResoTher-CS002 | P2 |
Recruiting |
ST Elevation Myocardial Infarction |
2025-12-21 |